Intervention
RTB101
Executive intelligence snapshot
Current reviewed view
Phase 3 showed no reduction in clinically symptomatic respiratory illness despite greater interferon-induced antiviral gene expression.
This profile includes 3 reviewed relationship(s) and 5 reviewed source(s).
This view is bounded by reviewed evidence and does not provide a recommendation or a claim beyond the stated review date.
Evidence state
Source-reviewed
Evidence state
What the evidence supports
Phase 3 showed no reduction in clinically symptomatic respiratory illness despite greater interferon-induced antiviral gene expression.
Evidence boundary
Key limitations
- The result did not show that TORC1 modulation or interferon-pathway engagement failed; antiviral gene induction was observed and tolerability was acceptable.
Does not establish efficacy, mechanism falsification, approval, utility, rejuvenation, or investment attractiveness.
Not established
Key unknowns
- Dose, route, population, and outcomes not recorded in this reviewed profile remain unknown.
The reviewed evidence does not resolve this dimension beyond the recorded boundary.
Intelligence connections
Related intelligence
Reviewed source layer
Evidence & sources
These cards show only metadata present in the reviewed source registry.
bibliographic index
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults
PubMed
Reference: 33977284
Reviewed: 2026-08-06
trial registry
RTB101 for COVID-19 Prevention in Nursing Home Residents
ClinicalTrials.gov
Reference: NCT04409327
Reviewed: 2026-08-06
trial registry
A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly
ClinicalTrials.gov
Reference: NCT04668352
Reviewed: 2026-08-06
trial registry
Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly
ClinicalTrials.gov
Reference: NCT04139915
Reviewed: 2026-08-06
trial registry
Dose Finding Study of RTB101 for Respiratory Tract Infections in Older Adults
ClinicalTrials.gov
Reference: NCT03373903
Reviewed: 2026-08-06
Technical provenance
- Object key
intervention:LNPG-ENT-b2e53ade-05e0-4c62-b9f5-1fb84792b0b2- Source release
LNPG-REL-20260807-027- Mapping version
0.2.0- Presentation release
LNPG-REL-20260808-037- Projection hash
f84ca889a7b513083e0039bcb5c9b46f32658f9c01d795a089d2766c29155b98
Source identifiers
LNPG-SRC-0963f6fc-e77e-4522-a742-98b195f27724LNPG-SRC-364abcbd-f5ae-4e5c-a7ad-2a21fd699db1LNPG-SRC-5ace5b58-6a68-416c-8775-124d5d88d23eLNPG-SRC-a322990a-b6a1-499f-9a09-5201066a0484LNPG-SRC-c75a598b-c5df-4a78-a5d6-2681e852505a
Directed relationship identities
edge:00192—intervention_exactly_links_companyedge:00193—intervention_tested_in_trialedge:00194—intervention_tested_in_trial
Scores are not displayed because no score methodology is qualified for this profile.
Presentation contract
- Snapshot mode
DIRECT_GOVERNED_SUMMARY